questionText: To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of the repayment rate for newer medicines under the Voluntary Scheme for Branded Medicines Pricing, Access and Growth on the UK life sciences sector.
answerText: The voluntary scheme for branded medicines pricing, access, and growth (VPAG) is a unique partnership between the Government and the pharmaceutical industry and includes a range of commitments to support innovation and improve National Health Service acce...
heading: Voluntary Scheme for Branded Medicines Pricing, Access and Growth